HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Sharma, S. Articles by Cobanoglu, A. Search for Related Content PubMed PubMed Citation Articles by Sharma, S. Articles by Cobanoglu, A.

European Journal of Cardio-Thoracic Surgery, Vol 10, 616-620, Copyright © 1996 by European Association for Cardio-thoracic Surgery

ARTICLES

Gastrointestinal complications after orthotopic cardiac transplantation

S Sharma, V Reddy, G Ott, B Sheppard, R Ratkovec, R Hershberger, D Norman, J Hosenpud and A Cobanoglu
Department of Cardiopulmonary Surgery, Oregon Health Sciences University, Portland 97201-3098, USA.

OBJECTIVE AND METHODS: A retrospective chart review was performed on all patients undergoing orthotopic cardiac allograft transplant at Oregon Health Sciences University. Our purpose was to evaluate the incidence of gastrointestinal complications in these patients, and to assess the effect of immunosuppression. RESULTS: From December, 1985, to June, 1994, 240 recipients underwent 250 orthotopic cardiac allograft transplants at Oregon Health Sciences University with a 30 day mortality of 15 patients (6.3 +/- 3.0%). Of the 225 operative survivors, the follow-up ranges from 1.0 month to 8.8 years with a mean of 39.9 +/- 1.9 months. In our population of late survivors, 21 recipients (9.3%) have had gastrointestinal complications (GIC). Hepatobiliary (29%), peptic ulcer (14%), and pancreatic (14%) complications were the most prevalent. Surgical intervention was required in 19 patients (90%). Twelve procedures (63%) were either emergently or urgently performed, and seven procedures (37%) carried out electively. Operative mortality was 33% in those patients with an emergent or urgent intervention. There was no operative mortality among those who had an elective procedure. CONCLUSION: Maintenance prednisone dose was higher in patients with GIC than in those patients without GIC, 16.1 +/- 2.5 mg versus 7.3 +/- 0.2 mg (P = 0.001), respectively. However, immunosuppression therapy for rejection episodes (i.e., Solumedrol megapulse or OKT3 therapy) was not related to an increased incidence of GIC. We present a review of our 21 cardiac transplant recipients to emphasize the potential for severe GIC and their corresponding perioperative morbidity and mortality.